Turning Big Data into Big Money
Technology to Mitigate the Rising Big Data Cost
Big Data & Insights: Oil for the Digital Age
Leveraging Biomedical Big Data: A Hybrid Solution
Lambda Architecture-Ideal for Healthcare Big Data Use Cases
Shahid Shah, Co Founder and CEO, Netspective Communications
Big Data: Separating the Hype from Reality in Corporate Culture
Brett MacLaren, VP, Enterprise Analytics, Sharp HealthCare
Leveraging Big Data for Data Analytics
Derek Wilson, President & CEO, CDO Advisors LLC
Big Data, Analytics and Metrics to Make Better Decisions
Anne Legg, VP - Strategic Marketing, Credit Union Solutions, Fiserv
Thank you for Subscribing to CIO Applications Weekly Brief
Blockchain and the Future of Genomics
While human genetic make-up across species is identical, it is only 0.1 percent that has unique variations; this variation influence individuals toward diseases and even temperamental bias-ownership of this data becomes a price commodity. However, in a contested environment where the right to privacy is fought around the world, protecting the data becomes all the more important, especially for the human genome.
Blockchain has attracted considerable interest as a compelling alternative to the closed architectures and proprietary exploits of the existing data market for genomics—promising a secure and open protocol for the code of life instead.
Nonprofit Personal Genome Project (PGP)—a ‘Wikipedia’ of open-access human genomic data, in pursuit of advancing science, relied on people who forfeited privacy and ownership. This is one example in the market where they have informed people before collecting information and also leveraging the knowledge in the advancements of genomics.
In contrast, hospitals till date may have collected information in the guise of a consent form. This needs to change. The solution lies in the adoption of blockchain technology in the healthcare systems. A blockchain model would allow interested buyers to pitch in cash for someone’s sequence in return for access to their data, say two pharmaceutical companies.
In this increasingly opaque genomics data landscape, tokenization opens the possibility of flexibility and granular consent to allow various scenarios, private companies monetize the genotypic data generated by their consumers, and the sequence data is fragmented across proprietary, centralized silos, whether in the unmanageable legacy systems of healthcare and research institutions or the private troves of biotech companies.
Bringing genomics to the blockchain would allow the circulation needed to speed up research while protecting this unique personal information by separating anonymous identities from cryptographic identifiers. The users remain in control of their data and decide exactly with whom and for what purposes they share it. In turn, this access would be tracked on an auditable and immutable booklet. The users remain in control of their data and decide exactly who they share it with and for what purposes. This access would be tracked in turn on an auditable and unchanging booklet.
The advent of genomics raises questions that science alone cannot solve. Blockchain could be just the key to create the fair and transparent means of ownership and circulation that would ensure that these helixes of fibrous biomaterial do not spiral out of control.